Journal article
Two year outcomes of "treat and extend" Intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration
D Barthelmes, V Nguyen, V Daien, A Campain, R Walton, R Guymer, N Morlet, AP Hunyor, RW Essex, JJ Arnold, MC Gillies
Retina | LIPPINCOTT WILLIAMS & WILKINS | Published : 2018
Abstract
Purpose: To report 24-month outcomes of a treat and extend (T&E) regimen using aflibercept in eyes with neovascular age-related macular degeneration. Methods: This was a database observational study that included treatment-naive eyes with neovascular age-related macular degeneration tracked by the Fight Retinal Blindness! outcome registry completing 24 months of sole monotherapy with aflibercept treatment under a T&E regimen between November 1, 2012 and January 31, 2014. Locally weighted scatterplot smoothing curves were used to display visual acuity outcomes. Main outcome measures were change in visual acuity at 24 months and number of injections and visits during the study period. Results:..
View full abstractGrants
Funding Acknowledgements
Supported by a grant from the Royal Australian NZ College of Ophthalmologists Eye Foundation (2007-2009) and a grant from the National Health and Medical Research Council, Australia (NHMRC 2010-2012). M. C. Gillies is a Sydney Medical Foundation Fellow and is supported by an NHMRC practitioner fellowship, and R. Guymer is supported by a NHMRC Principal research fellowship. D. Barthelmes was supported by the Walter and Gertrud Siegenthaler Foundation Zurich, Switzerland and the Swiss National Foundation. Funding was also provided by Novartis and Bayer. These supporting organizations had no role in the design or conduct of the research. M. C. Gillies and R. Guymer are members of advisory boards for Novartis and Bayer. D. Barthelmes received research grants from Novartis and Bayer. V. Daien received travel grants from Novartis and Bayer. None of the other authors have no any conflicting interests to disclose.